Skip to content
Screener

Myriad Genetics MYGN Prenatal — Revenue

Other product segments

Cancer Care Continuum
$120.2M—
Hereditary Cancer
$96.8M+2.5%
Prenatal Health
$41.9M—
Mental Health
$38.3M—

Similar metrics at other companies

BillionToOne, Inc. logo
BLLNPrenatal — Revenue
$94.25M+54.9%
Atlas Energy Solutions logo
AESIRental Revenue — Revenue
$26.97M+71.6%
ALT
ALTGRental Revenue — Revenue
$44.9M-3.0%
Titan Machinery logo
TITNRental — Revenue
$8.5M+39.5%
Alset Inc. logo
AEIRental — Revenue
$726.66K+1.2%
Hilton Grand Vacations logo
HGVRental — Revenue
$183M+5.2%

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$310.86M-46.0%
Enterprise value$396.36M-38.7%
P/S0.4×-0.3×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%—

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Myriad Genetics’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:01 PM EST
Fiscal year
FY2025
Accession
0000899923-26-000018
(In millions)Years Ended December 31, 2025Years Ended December 31, 2024Years Ended December 31, 2023
Hereditary Cancer$372.4$364.5$327.8
Tumor Profiling121.7125.8135.6
Prenatal186.3177.1151.3
Mental Health144.1170.2138.5
Total revenue$824.5$837.6$753.2

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FAQ

What is Myriad Genetics's prenatal — revenue?
Myriad Genetics (MYGN) reported prenatal — revenue of $44.9M in Q4 2025.
How has Myriad Genetics's prenatal — revenue changed year-over-year?
Myriad Genetics's prenatal — revenue decreased by 0.0% year-over-year, from $44.9M to $44.9M.
What is the long-term trend for Myriad Genetics's prenatal — revenue?
Over 2 years (2023 to 2025), Myriad Genetics's prenatal — revenue has grown at a 11.0% compound annual growth rate (CAGR), from $151.3M to $186.3M.
What does prenatal — revenue mean?
Represents the total gross income generated specifically from the sale and delivery of molecular diagnostic prenatal testing services. This metric tracks the commercial performance of the prenatal product line, reflecting market adoption and pricing power within the reproductive health diagnostics sector. It serves as a key indicator of the company's ability to capture share in the prenatal screening market.

Ask your AI about Myriad Genetics's prenatal — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude